Product characterization questions and partial or inconsistent clinical data are among the more common reasons why the US FDA denies, or seeks additional information about, a request for regenerative medicine advanced therapy (RMAT) designation, according to the head of the office that oversees the expedited pathway.
Manufacturing remains a focus of concern during the intensive interactions between the agency and sponsor upon receipt of RMAT designation,...